[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":320},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,73,100,138,188,211,235,262,285,302],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100563385","phase-3-a-study-to-compare-the-efficacy-and-safety-of-bms-986393-versus-standard-regimens-in-adult-participants-with-relapsed-or-refractory-and-lenalidomide-exposed-multiple-myeloma-quintessential-2-100563385",false,"NCT06615479","A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma","Inclusion Criteria\n\n* Participants must have relapsed or refractory multiple myeloma (RRMM).\n* Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide.\n* Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.\n* Participants must have measurable disease during screening.\n* Participants must have adequate organ function.\n* Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.\n\nExclusion Criteria\n\n* Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).\n* Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.\n* Participants must not need urgent treatment due to rapidly progressing MM.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","18 Years",{"count":19,"type":20},440,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.",[26],"Relapsed or Refractory Multiple Myeloma (RRMM)",[28,29,30,31,32,33,34],"Relapsed or Refractory Multiple Myeloma","Multiple Myeloma","BMS-986393","Chimeric Antigen Receptor T-cell (CAR T-cell)","CAR T-cell Therapy","Arlocabtagene Autoleucel","Arlo-cel","RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-18","ACTUAL",{"date":41,"type":39},"2025-03-12",{"date":43,"type":20},"2032-06-22",{"name":45,"class":46},"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","INDUSTRY",141,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100618741","phase-3-a-study-to-compare-the-efficacy-and-safety-of-bms-986353-zolacabtagene--autoleucel--zola-cel-cd19-car-t-cells-versus-standard-of-care-in-participants-with-active-systemic-sclerosis-100618741","NCT07335562","A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel \u002F Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis","A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (Breakfree-SSc)","Breakfree-SSc","Inclusion Criteria\n\n\\- Participants must fulfill the 2013 American College of Rheumatology (ACR) \u002F European League Against Rheumatism (EULAR) classification criteria for Systemic Sclerosis (SSc), and additionally have the following:.\n\ni) Positive Antinuclear Antibodies (ANA) with nucleolar pattern and\u002For anti-Topoisomerase I (anti-Scl-70) antibodies.\n\nii) Confirmation of Interstitial Lung Disease (ILD) on centrally read High-Resolution Computed Tomography (HRCT) with ≥ 10% total lung involvement, with at least one of the following attributed to active SSc:.\n\nA. Arthritis.\n\nB. Myositis.\n\nC. Carditis.\n\nD. Progressive skin disease.\n\nE. Elevated inflammatory markers.\n\n\\- Participants must have a non-response or intolerance despite ≥ 6 months of treatment with at least one immunomodulatory drug. Non-response is defined as a patient, who in the opinion of the investigator, is not adequately controlled\u002Ftreated and requires treatment escalation.\n\nExclusion Criteria\n\n* Participants must not have a requirement for supplemental oxygen therapy and\u002For Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) ≤ 40% (Hemoglobin (Hgb) corrected) at screening.\n* Participants must not have moderate to severe Pulmonary Arterial Hypertension (PAH) requiring PAH-specific combination treatment\n* Participants must not have pulmonary comorbidity including chronic obstructive pulmonary disease or asthma requiring daily oral corticosteroids, cigarette smoking (including e-cigarettes) within 3 months before screening or unwilling to avoid smoking throughout the study, and\u002For clinically significant abnormalities on HRCT not attributable to SSc assessed by the central reader at screening.\n* Participants must not have gastrointestinal (GI) dysmotility requiring Total Parenteral Nutrition (TPN).\n* Participants must not have current gangrene of a digit\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","16 Years",{"count":58,"type":20},92,[23],"The purpose of this study is to compare the efficacy and safety of BMS-986353 versus standard of care in participants with active Systemic Sclerosis",[62],"Systemic Sclerosis","NOT_YET_RECRUITING","2026-07-31",{"date":66,"type":39},"2026-08-03",{"date":68,"type":20},"2026-08-29",{"date":70,"type":20},"2030-11-11",{"name":45,"class":46},56,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},"100594115","phase-2-a-study-of-the-efficacy-and-safety-of-lisocabtagene-maraleucel-liso-cel-as-first-line-therapy-in-adults-with-transplant-ineligible-primary-central-nervous-system-lymphoma-100594115","NCT07015242","A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients","Inclusion Criteria\n\n* Participant must be 18 years or older at the time of signing the informed consent form (ICF).\n* Histologically confirmed primary central nervous system (CNS) lymphoma (PCNSL) prior to screening, as assessed by local pathology.\n* Transplant-ineligible based on physician's assessment and meeting at least one of the following criteria: age ≥65 years or HCT-CI (Hematopoietic Cell Transplantation-specific Comorbidity Index) score ≥3.\n* Participant must be suitable, per investigator, to receive a high dose methotrexate (HD-MTX) based treatment regimen.\n* Prior to signing ICF, anti-cancer therapy for the treatment of PCNSL must be limited to HD-MTX based standard of care regimens with a minimum of 4 and maximum of 6 doses of MTX. Corticosteroids used as part of standard-of-care management for PCNSL symptom control are permitted prior to ICF signature but must be discontinued at the time of ICF signature. For medical conditions other than PCNSL, non-therapeutic corticosteroids use may be permitted on study.\n* Prior to ICF enrollment, participant's disease must be sensitive to prior high-dose methotrexate-based (HD-MTX) regimens, as demonstrated by a complete response (CR, no remaining signs of PCNSL) or a partial response (PR, signs of PNCSL mostly gone) per Investigator's assessment, based on the International Primary CNS Lymphoma Collaborative Group (IPCG) criteria.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Individuals of childbearing potential (IOCBP) must have a negative highly sensitive pregnancy test within 24 hours prior to the start of study intervention.\n\nExclusion Criteria\n\n* Participant has a diagnosis of secondary CNS lymphoma due to systemic disease.\n* Primary intraocular lymphoma (PIOL)\u002F Primary vitreoretinal lymphoma (PVRL), isolated cerebrospinal fluid (CSF) disease, or a relapsed or refractory PCNSL.\n* Any significant medical condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he\u002Fshe was to participate in the study based on investigator's judgement.\n* History of another primary malignancy that has not been in remission for ≥2 years.\n* Prior treatment with CAR T-cell or any other gene therapy product that utilizes human genome-editing technology.\n* History of or active human immunodeficiency virus (HIV).\n* Active hepatitis B or active hepatitis C.\n* Active autoimmune disease requiring immunosuppressive therapy.\n* History of prior allogeneic transplant, or solid organ transplant requiring immunosuppressive therapy.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":81,"type":20},65,[83],"PHASE2","The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi\u002Fliso-cel\u002FBMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).",[86],"Lymphoma",[88,89,90],"primary CNS lymphoma","newly diagnosed","JCAR017","2026-07-27",{"date":93,"type":39},"2026-07-29",{"date":95,"type":39},"2025-11-06",{"date":97,"type":20},"2028-12-10",{"name":45,"class":46},40,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100525446","phase-1-a-study-to-evaluate-the-safety-effectiveness-and-tolerable-dose-of-arlocabtagene-autoleucel-bms-986393-in-novel-combinations-in-participants-with-relapsed-andor-refractory-multiple-myeloma-100525446","NCT06121843","A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and\u002For Refractory Multiple Myeloma","A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and\u002For Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component","Inclusion Criteria:\n\n* History of relapsed and\u002For refractory multiple myeloma (RRMM) treated with at least 3 (Part 1), history of RRMM or at least 1 but not greater than 3 prior anti-myeloma treatment (PAMT) regimens (Part 2, Arms A, B, C, and D); history of quadruple class exposed RRMM having received BCMA TCE as the most recent line of therapy (Part 2, Arm E).\n* Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).\n* Eastern Cooperative Oncology Group performance status of 0-1.\n* Adherence to contraception requirements.\n\nExclusion Criteria:\n\n* Prior treatment with alnuctamab (Arm A), mezigdomide (Arms B and E), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).\n* Prior treatment with GPRC5D-targeting therapies as of Protocol Amendment 02 (Part 1 and Part 2).\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",{"count":108,"type":20},187,[110],"PHASE1","The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and\u002For refractory multiple myeloma (RRMM).",[29],[30,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128],"Relapsed Multiple Myeloma","Refractory Multiple Myeloma","First-in-human","Alnuctamab","Mezigdomide","Iberdomide","CC-95266","GPRC5D","GPRC5D CAR T","Cell Therapy","CAR T cell therapy","Combination therapy","elranatamab","arlocabtagene autoleucel","arlo-cel","2026-07-15",{"date":131,"type":39},"2026-07-16",{"date":133,"type":39},"2024-02-22",{"date":135,"type":20},"2028-08-01",{"name":45,"class":46},19,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},"100601841","phase-1-a-study-of-healthy-donor-cd19-targeted-allogeneic-car-t-cells-in-participants-with-severe-refractory-autoimmune-diseases-100601841","NCT07115745","A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases","A Phase 1, Multicenter, Open-label Study of BMS-986515, Healthy Donor Allogeneic CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases","Inclusion Criteria\n\n\\- Systemic lupus erythematosus (SLE) population:.\n\ni) Diagnosis of SLE based on the 2019 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR).\n\nii) Participant must be positive for at least one of the following antibodies at screening: anti-nuclear antibody, anti-dsDNA, anti-histone, anti-chromatin or anti-Sm antibody.\n\niii) Inadequate response or intolerance to steroids and immunosuppressive therapies.\n\niv) Participants must have active disease at screening.\n\n\\- Inflammatory myopathy (IIM) population:.\n\ni) Participants meeting the 2017 American College of Rheumatology (ACR) \u002F European League Against Rheumatism (EULAR) classification criteria.\n\nii) Participants must meet criteria for with severe, refractory IIM. iii) Participants who had inadequate response to steroids and prior immunosuppressive therapies.\n\niv) Evidence of active disease.\n\n\\- Systemic sclerosis (SSc) population:.\n\ni) Participant must fulfill the 2013 American College of Rheumatology (ACR)\u002F European League Against Rheumatism (EULAR) classification criteria for systemic sclerosis.\n\nii) Inadequate disease response or intolerance to prior therapies. iii) Participants diagnosed with progressive systemic sclerosis including skin disease and\u002For interstitial lung disease.\n\n\\- Rheumatoid arthritis (RA) population:.\n\ni) Participants with difficult to treat RA. ii) Participants with a diagnosis of RA meeting 2010 ACR\u002FEULAR criteria. iii) Rheumatoid arthritis disease activity at screening and baseline visit. iv) Inadequate disease response or intolerance to standard of care therapy.\n\nExclusion Criteria\n\n\\- All participants:.\n\ni) Any other systemic autoimmune disease. ii) Pregnant or nursing women. iii) Active hepatitis B, C or HIV. iv) Prior history of malignancies. v) Uncontrolled or active infection. vi) History of certain cardiovascular conditions within 6 months prior to screening.\n\nvii) Previous CAR-T cell therapy. viii) Significant lung impairment. ix) Inadequate organ function. x) Active, clinically significant, central nervous system (CNS) disorders.\n\n* SLE population:.\n\n  i) Participants who have SLE because of drugs or have other autoimmune diseases along with SLE.\n* IIM population:.\n\n  i) Participants who have other forms of myopathies other than IIM. ii) Severe muscle damage.\n* SSc population:.\n\n  i) People who have high blood pressure in the arteries of the lungs caused by SSc, which needs regular treatment to keep it under control.\n\nii) Rapidly deteriorating SSc, or history of severe kidney disease.\n\n* RA population:.\n\n  i) People who have additional autoimmune diseases along with RA.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",{"count":146,"type":20},125,[110],"The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.",[150],"Refractory Autoimmune Diseases",[152,123,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178],"CAR-T","Autoimmune disease","Systemic lupus erythematosus","idiopathic inflammatory myopathy","systemic sclerosis","rheumatoid arthritis","Musculoskeletal Diseases","Myositis","Lupus Erythematosus, Systemic","Scleroderma, Systemic","Scleroderma, Diffuse","Autoimmune Diseases","Sclerosis","Skin Diseases","Connective tissue diseases","BMS-986515","Allogeneic CAR T","CD19 Allogeneic CAR T","AlloCAR T, Cell Therapy","CAR T","SLE","Lupus Nephritis","SSc","IIM","Polymyositis","Dermatomyositis","RA","2026-07-13",{"date":181,"type":39},"2026-07-14",{"date":183,"type":39},"2025-09-04",{"date":185,"type":20},"2030-08-16",{"name":45,"class":46},28,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},"100639328","phase-2-study-of-zola-cel-bms-986353-in-participants-with-autoimmune-cytopenia-breakfree-aice-100639328","NCT07603557","Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)","A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)","Inclusion Criteria\n\nInclusion Criteria for ITP\n\n* Documented clinical diagnosis of chronic ITP (cITP) without other clinical manifestations of systemic autoimmune disease.\n* Has relapsed after or is intolerant to corticosteroids (with or without intravenous immunoglobulin (IVIG) or anti-Rh0(D) Ig) AND has failed, relapsed after, or is intolerant to therapies with ≥ 2 mechanisms of action, with at least one being immunosuppressive or immunomodulatory.\n\nPlatelet count \\\u003C 30 × 109\u002FL. For participants on thrombopoietin receptor agonist (TPO-RA): platelet count \\\u003C 50 × 109\u002FL.\n\nInclusion Criteria for AIHA\n\n* Documented clinical diagnosis of AIHA (including warm autoimmune hemolytic anemia (wAIHA), cold agglutinin disease (CAD), or mixed AIHA) without other clinical manifestations of systemic autoimmune disease.\n\n  o wAIHA and mixed warm and cold AIHA: Failed, relapsed after, or is intolerant to at least 2 prior lines of treatment with 2 mechanisms of action (not including corticosteroids or IVIG), one of which is an anti-CD20 monoclonal antibody unless there is a documented contraindication.\n\n  o CAD (all of the following must apply): Failed, relapsed after, or is intolerant to at least 2 prior lines of treatment with 2 mechanisms of action, one of which is an anti-CD20 monoclonal antibody with or without chemotherapy unless there is a documented contraindication.\n* Hb \\\u003C10 g\u002FdL without red blood cell transfusion, or transfusion dependent\n* Documented hemolysis\n\nExclusion Criteria\n\nMedical Conditions\n\n* ITP or AIHA associated with: Evans syndrome, other systemic autoimmune disease or single organ autoimmune disease requiring systemic immunosuppressive therapy, hepatitis C virus, HIV, drug induced (eg, non-steroidal anti-inflammatory drug (NSAIDS), trimethoprim\u002Fsulfamethoxazole (TMP-SMX), anticonvulsants), surgical procedures, or hematologic malignancies.\n* COVID-19 Vaccine-induced immune thrombotic thrombocytopenia\n* Prior history of solid organ malignancies, unless the participant has been free of the disease for ≥ 2 years.\n\nLaboratory Test Findings\n\n* Peripheral blood ANC \\\u003C 1.5 × 109\u002FL or requiring G-CSF or GM-CSF support o ALT\u002FAST: ITP: ALT\u002FAST: \\> 3 × ULN AIHA: ALT \\> 3 ULN. AST up to 5 × ULN may be permitted. o Bilirubin: ITP: total bilirubin \\> 1.5 × ULN AIHA: direct bilirubin \\> 1.5 × ULN o International normalized ratio (INR) \\> 1.5 × ULN\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":196,"type":20},52,[83],"The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and autoimmune hemolytic anemia (AIHA).",[200,201],"Chronic Immune Thrombocytopenia","Autoimmune Hemolytic Anemia","2026-07-08",{"date":204,"type":39},"2026-07-09",{"date":206,"type":20},"2026-08-31",{"date":208,"type":20},"2030-05-06",{"name":45,"class":46},8,{"id":212,"slug":213,"hasResults":11,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":196},"100538929","phase-2-study-of-arlocabtagene-autoleucel-bms-986393-a-gprc5d-directed-car-t-cell-therapy-in-adult-participants-with-relapsed-or-refractory-multiple-myeloma-100538929","NCT06297226","Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)","QUINTESSENTIAL","Inclusion Criteria\n\n* Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.\n* Received at least 4 classes of MM treatment \\[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT).\n* Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.\n* Participants must have measurable disease during screening.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria\n\n* Active or history of central nervous system involvement with MM.\n* Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded.\n* Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",{"count":220,"type":20},230,[83],"The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.",[29],[28,29,30,225,226,33],"CAR T Cell Therapy","RRMM","2026-05-26",{"date":229,"type":39},"2026-05-28",{"date":231,"type":39},"2024-03-21",{"date":233,"type":20},"2032-06-30",{"name":45,"class":46},{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":4,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":243,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":137},"100527860","phase-1-a-study-to-assess-bms-986453-in-participants-with-relapsed-andor-refractory-multiple-myeloma-100527860","NCT06153251","A Study to Assess BMS-986453 in Participants With Relapsed and\u002For Refractory Multiple Myeloma","A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and\u002For Refractory Multiple Myeloma","Inclusion Criteria:\n\n* Participants must have a diagnosis of multiple myeloma with relapsed and\u002For refractory disease.\n* Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.\n* Participants in Part A and Part B Cohort 1 and in Part B Cohort 2 must have relapsed\u002Frefractory multiple myeloma and received previous antimyeloma therapy, including a proteasome inhibitor and an immunomodulatory agent.\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate organ function.\n\nExclusion Criteria:\n\n* Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.\n* Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.\n* Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.\n* Other protocol-defined inclusion\u002Fexclusion criteria apply.",{"count":108,"type":20},[110],"The purpose of this study is to assess BMS-986453 in participants with relapsed and\u002For refractory multiple myeloma (RRMM).",[246],"Relapsed and\u002For Refractory Multiple Myeloma",[248,249,250,251,171,252,29,253],"Dual Targeting","BCMAxGPRC5D","GPRC5DxBCMA","BMS-986453","CART","Relapsed and\u002For Refractory","2026-03-16",{"date":256,"type":39},"2026-03-18",{"date":258,"type":39},"2024-01-23",{"date":260,"type":20},"2030-05-02",{"name":45,"class":46},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":284},"100577128","a-study-to-patients-with-relapsedrefractory-follicular-lymphoma-treated-with-liso-cel-lisocabtagene-maraleucel-in-the-post-marketing-setting-100577128","NCT06794268","A Study to Patients With Relapsed\u002FRefractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting","Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed\u002FRefractory Follicular Lymphoma in the Postmarketing Setting","Inclusion Criteria:\n\n• Participants must have been treated in the post-marketing setting with at least 1 infusion of lisocabtagene maraleucel (liso-cel) used for the treatment of relapsed\u002Frefractory (R\u002FR) follicular lymphoma (FL), including FL Grade 1, Grade 2 and Grade 3a, within the FDA-approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA\n\nExclusion Criteria:\n\n* Participants known to be participating in investigational studies at the time of liso-cel, infusion\n* Participants treated with liso-cel for the treatment of R\u002FR FL Grade 3b\n* Participants treated with non-conforming chimeric antigen receptor (CAR) T-cell product",{"count":270,"type":20},300,"OBSERVATIONAL","The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities",[274],"Follicular Lymphoma",[274],"2025-02-21",{"date":278,"type":39},"2025-02-24",{"date":280,"type":39},"2025-02-04",{"date":282,"type":20},"2044-08-31",{"name":45,"class":46},1,{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":297,"startDateStruct":298,"completionDateStruct":299,"leadSponsor":301,"locationsCount":284},"100576696","a-study-of-patients-with-relapsedrefractory-mantle-cell-lymphoma-treated-with-lisocabtagene-maraleucel-in-the-post-marketing-setting-100576696","NCT06788652","A Study of Patients With Relapsed\u002FRefractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting","Non-interventional Cohort Study of Patients Treated With Lisocabtagene Maraleucel (Liso-cel) for Relapsed\u002FRefractory Mantle Cell Lymphoma in the Post-Marketing Setting","Inclusion Criteria:\n\n• Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA\n\nExclusion Criteria:\n\n* Participants known to be participating in investigational studies at the time of liso-cel infusion.\n* Participants treated with non-conforming CAR T-cell product.",{"count":270,"type":20},"The purpose of this study is to understand the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) for the treatment of Mantle Cell Lymphoma (MCL).",[295],"Mantle Cell Lymphoma (MCL)",[295],{"date":278,"type":39},{"date":280,"type":39},{"date":300,"type":20},"2044-09-30",{"name":45,"class":46},{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":271,"phases":4,"briefSummary":310,"conditions":311,"keywords":314,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":317,"leadSponsor":319,"locationsCount":284},"100576695","a-study-of-patients-with-relapsedrefractory-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-treated-with-lisocabtagene-maraleucel-in-the-post-marketing-setting-100576695","NCT06788639","A Study of Patients With Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting","Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed\u002FRefractory Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma in the Post-Marketing Setting","Inclusion Criteria:\n\n• Participants must have been treated in the post-marketing setting with ≥1 infusion of lisocabtagene maraleucel used for the treatment of relapsed\u002Frefractory (R\u002FR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) within the approved indication and dosage per the United States Prescribing Information (USPI) and product specifications approved for commercial release in the USA\n\nExclusion Criteria:\n\n* Participants known to be participating in investigational studies at the time of lisocabtagene maraleucel infusion\n* Patients treated with non-conforming CAR T-cell product",{"count":270,"type":20},"The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities",[312,313],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[312,313],{"date":278,"type":39},{"date":280,"type":39},{"date":318,"type":20},"2044-06-30",{"name":45,"class":46},""]